321 related articles for article (PubMed ID: 18339879)
1. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D
Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879
[TBL] [Abstract][Full Text] [Related]
2. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
3. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.
Elechalawar CK; Hossen MN; Shankarappa P; Peer CJ; Figg WD; Robertson JD; Bhattacharya R; Mukherjee P
Int J Nanomedicine; 2020; 15():991-1003. PubMed ID: 32103952
[TBL] [Abstract][Full Text] [Related]
4. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
Glazer ES; Zhu C; Massey KL; Thompson CS; Kaluarachchi WD; Hamir AN; Curley SA
Clin Cancer Res; 2010 Dec; 16(23):5712-21. PubMed ID: 21138869
[TBL] [Abstract][Full Text] [Related]
6. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
7. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
[TBL] [Abstract][Full Text] [Related]
9. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Philip PA; Benedetti J; Corless CL; Wong R; O'Reilly EM; Flynn PJ; Rowland KM; Atkins JN; Mirtsching BC; Rivkin SE; Khorana AA; Goldman B; Fenoglio-Preiser CM; Abbruzzese JL; Blanke CD
J Clin Oncol; 2010 Aug; 28(22):3605-10. PubMed ID: 20606093
[TBL] [Abstract][Full Text] [Related]
10. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Morgan MA; Parsels LA; Kollar LE; Normolle DP; Maybaum J; Lawrence TS
Clin Cancer Res; 2008 Aug; 14(16):5142-9. PubMed ID: 18698032
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R; Muenter MW; Huber PE; Nill S; Friess H; Timke C; Didinger B; Buechler P; Heeger S; Herfarth KK; Abdollahi A; Buchler MW; Debus J
BMC Cancer; 2005 Oct; 5():131. PubMed ID: 16219105
[TBL] [Abstract][Full Text] [Related]
13. GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells.
Wang L; An Y; Yuan C; Zhang H; Liang C; Ding F; Gao Q; Zhang D
Int J Nanomedicine; 2015; 10():2507-19. PubMed ID: 25848268
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.
Arya G; Vandana M; Acharya S; Sahoo SK
Nanomedicine; 2011 Dec; 7(6):859-70. PubMed ID: 21550422
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and therapeutic efficacy of a gold nanoparticle-based targeted drug delivery system against pancreatic cancer.
Elechalawar CK; Gulla SK; Roy RV; Means N; Zhang Y; Asifa S; Robertson DJ; Xu C; Bhattacharya R; Mukherjee P
Cancer Lett; 2024 May; 589():216810. PubMed ID: 38494151
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Burris H; Rocha-Lima C
Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
[TBL] [Abstract][Full Text] [Related]
17. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo.
Khan JA; Kudgus RA; Szabolcs A; Dutta S; Wang E; Cao S; Curran GL; Shah V; Curley S; Mukhopadhyay D; Robertson JD; Bhattacharya R; Mukherjee P
PLoS One; 2011; 6(6):e20347. PubMed ID: 21738572
[TBL] [Abstract][Full Text] [Related]
18. Her signaling in pancreatic cancer.
Burtness B
Expert Opin Biol Ther; 2007 Jun; 7(6):823-9. PubMed ID: 17555368
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
20. Tumor resensitization to erlotinib following brief substitution of cetuximab.
Epstein RJ; Leung TW
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1111-2. PubMed ID: 18283460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
